While modified cytosine nucleosides, such as 5-aza-cytidine, have been approved to treat myelodysplastic syndrome, such demethylators are not DNMT isozyme specific and require incorporation into DNA to exert their effects [22], suggesting that there is room for improvement in probe development. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.